321 related articles for article (PubMed ID: 32445177)
1. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.
Joseph C; Alsaleem M; Orah N; Narasimha PL; Miligy IM; Kurozumi S; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jul; 182(2):267-282. PubMed ID: 32445177
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
Kariri YA; Joseph C; Kurozumi S; Toss MS; Alsaleem M; Raafat S; Mongan NP; Aleskandarany MA; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jan; 179(2):349-357. PubMed ID: 31679074
[TBL] [Abstract][Full Text] [Related]
3. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
Kurozumi S; Joseph C; Sonbul S; Gorringe KL; Pigera M; Aleskandarany MA; Diez-Rodriguez M; Nolan CC; Fujii T; Shirabe K; Kuwano H; Storr S; Martin SG; Ellis IO; Green AR; Rakha EA
Breast Cancer Res Treat; 2018 Aug; 170(3):525-533. PubMed ID: 29633055
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer.
Kariri YA; Alsaleem M; Joseph C; Alsaeed S; Aljohani A; Shiino S; Mohammed OJ; Toss MS; Green AR; Rakha EA
Breast Cancer Res Treat; 2021 Jan; 185(2):293-305. PubMed ID: 33073304
[TBL] [Abstract][Full Text] [Related]
7. The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
El Ansari R; Craze ML; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2018 Apr; 118(8):1115-1122. PubMed ID: 29545595
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
Althobiti M; Muftah AA; Aleskandarany MA; Joseph C; Toss MS; Green A; Rakha E
Breast Cancer Res Treat; 2020 Aug; 182(3):581-589. PubMed ID: 32524353
[TBL] [Abstract][Full Text] [Related]
9. Elevated Expression of RIOK1 Is Correlated with Breast Cancer Hormone Receptor Status and Promotes Cancer Progression.
Huang Z; Li X; Xie T; Gu C; Ni K; Yin Q; Cao X; Zhang C
Cancer Res Treat; 2020 Oct; 52(4):1067-1083. PubMed ID: 32599985
[TBL] [Abstract][Full Text] [Related]
10. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
[TBL] [Abstract][Full Text] [Related]
11. Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma.
Li Q; Chen B; Cai J; Sun Y; Wang G; Li Y; Li R; Feng Y; Han B; Li J; Tian Y; Yi L; Jiang C
PLoS One; 2016; 11(3):e0151815. PubMed ID: 27022952
[TBL] [Abstract][Full Text] [Related]
12. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
[TBL] [Abstract][Full Text] [Related]
13. Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.
Aleskandarany MA; Sonbul S; Surridge R; Mukherjee A; Caldas C; Diez-Rodriguez M; Ashankyty I; Albrahim KI; Elmouna AM; Aneja R; Martin SG; Ellis IO; Green AR; Rakha EA
Br J Cancer; 2017 Oct; 117(8):1176-1184. PubMed ID: 28829761
[TBL] [Abstract][Full Text] [Related]
14. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
[TBL] [Abstract][Full Text] [Related]
15. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.
Liu J; Ping W; Zu Y; Sun W
Int J Clin Exp Pathol; 2014; 7(9):6040-7. PubMed ID: 25337249
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
Kurozumi S; Joseph C; Sonbul S; Aleskandarany MA; Pigera M; Alsaleem M; Alsaeed S; Kariri Y; Nolan CC; Diez-Rodriguez M; Johnston S; Mongan NP; Fujii T; Shirabe K; Martin SG; Ellis IO; Green AR; Rakha EA
Breast Cancer Res Treat; 2018 Nov; 172(1):61-68. PubMed ID: 30056565
[TBL] [Abstract][Full Text] [Related]
17. High TNFRSF12A level associated with MMP-9 overexpression is linked to poor prognosis in breast cancer: Gene set enrichment analysis and validation in large-scale cohorts.
Yang J; Min KW; Kim DH; Son BK; Moon KM; Wi YC; Bang SS; Oh YH; Do SI; Chae SW; Oh S; Kim YH; Kwon MJ
PLoS One; 2018; 13(8):e0202113. PubMed ID: 30142200
[TBL] [Abstract][Full Text] [Related]
18. Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis.
Jiang H; Li H
BMC Cancer; 2021 Feb; 21(1):149. PubMed ID: 33568081
[TBL] [Abstract][Full Text] [Related]
19. The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients.
Khoshnaw SM; Rakha EA; Abdel-Fatah T; Nolan CC; Hodi Z; Macmillan RD; Ellis IO; Green AR
Breast Cancer Res Treat; 2013 Jan; 137(1):139-53. PubMed ID: 23225145
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Paish EC; Macmillan RD; Ellis IO; Green AR
Breast Cancer Res Treat; 2010 Jul; 122(1):45-53. PubMed ID: 19701705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
